CN101264347A - Drug-eluting coated on surface of sacculus catheter air bag for alleviating vascular restenosis - Google Patents
Drug-eluting coated on surface of sacculus catheter air bag for alleviating vascular restenosis Download PDFInfo
- Publication number
- CN101264347A CN101264347A CNA2007101504138A CN200710150413A CN101264347A CN 101264347 A CN101264347 A CN 101264347A CN A2007101504138 A CNA2007101504138 A CN A2007101504138A CN 200710150413 A CN200710150413 A CN 200710150413A CN 101264347 A CN101264347 A CN 101264347A
- Authority
- CN
- China
- Prior art keywords
- coated
- foley
- balloon surface
- medicine
- tube
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a medical coating layer coated on the gasbag surface of a balloon pipe which can release the narrowing of blood vessel and reduce free radical damage after operation, belonging to the field of the medical instruments, which comprises 1% to 99% of medicine and 1% to 99% of medical carrier, wherein the medical comprises a single oxidation resisting medicine, or a mixture of a plurality of oxidation resisting medicines, or a mixture of a single or a plurality of oxidation resisting medicines with blood vessel narrowing resisting medicines; the medicines are evenly coated on the surface of the gasbag all together or layer by layer. The medical coating layer coated on the gasbag surface of a balloon pipe has the advantages that through local medication the damage to human cells and organizations after blood transfusion due to myocardial ischemia can be effectively released and reduced and the cardiac dysfunction can be finally cured.
Description
Technical field
The present invention relates to medical instruments field, particularly a kind ofly adopt the alleviating vascular restenosis that anti-oxidation medicine coats and be coated in the medication coat of foley's tube balloon surface.
Background technology
Atherosclerosis is the important diseases that influences health, and the pathological changes that wherein feeds through to heart coronary artery is called coronary heart disease.Coronary heart disease often causes deficiency myocardial blood supply, and gently then angina pectoris is heavy then cause myocardial infarction, even dead.The U.S. in 2000 ischemic heart desease death accounts for 21.4% of dead sum, and wherein acute myocardial infarction death accounts for 8%.
It is clinical medical in recent years impressive progress that patients of acute myocardial infarction adopts the treatment of revascularization art, because dredging vascellum or reproduce blood vessel and make cardiac muscular tissue obtain the perfusion again of blood behind the ischemia really can be received excellent curative as a rule.Yet, recover again sometimes to increase the weight of myocardial structural damages and dysfunction on the contrary behind the blood flow, even cause severe arrhythmia.The damage that how can reduce ischemia-reperfusion effectively is the problem that domestic and international medical circle is paid close attention to always.
In recent years, along with the coronary artery balloon expandable forms applying of art, with the intravascular stent that contains radioactive substance is that patients with coronary heart disease brings glad tidings, but, preparation and use to carry out protection to lonizing radiation because containing the radioactive substance intravascular stent, it is very complicated that operation is implemented, simultaneously because therefore the problem that also exists the Excreta that must prevent to contain radioactive substance that environment is polluted makes it be restricted in clinical use.
Produced afterwards into preventing vascular restenosis drug-carried coat support, this type of medicine is at platelet GBIIb/IIIa receptor antagonist or influences cell division, quicken the cancer therapy drug of natural death of cerebral cells, but there is in controlled-release coating processing technology instability or the operation process damage to the rack surface controlled release layer, and be created in the too fast too high possibility of local blood drug level that causes of rate of release in the human body, bring the further risk of damage of myocardial cell.
Method by intravenous injection antioxidant (coenzyme Q10) also once was applied to clinical, because the time is short, can not keep local drug concentration, and curative effect is also undesirable.Therefore how local application and use which kind of ingredient collocation to become the another development trend of research medicine slow release stent with the cooperative effect that reaches treatment and protection.
The theoretical basis that the present invention is based on is carried out following analysis:
The basic theories of 1 free radical
Free radical is the group that has one or more unpaired electronics in out orbit, and this is the material that a class has greater activity.Free radical is the interior intermediate product [list of references 1] about catalytic aerobic metabolism process of enzyme system and electron transport chain electron transport of organism, also is the intermediate product that bio-tissue or cell form in some chemical damage process.It brings into play the effect of strong oxidizer in vivo directly or indirectly, thereby damage organism macromole and various kinds of cell composition, also can react with other materials (as nucleic acid, protein, lipid etc.), generate the oxide or the peroxide of this class material, to body cause damage [list of references 2].Free radical comprises ultra-oxygen anion free radical (O
2 -), hydroxy radical (OH), hydrogen peroxide (H
2O
2), singlet oxygen (O
2 -), hydroperoxyl radical (HOO), peroxy radical (ROO), nitric oxide free radical (NO), semiquinone free radical (QH), peroxynitrite base (ONOO
-); Alkane free radical (R), alkoxy free group (RO), alkane peroxy radical (ROO); Fat oxygen-derived free radicals (LO), fat peroxy radical (LOO) isoreactivity oxygen (ROS).With the intermediate product malonaldehyde (malondialdehyde MDA) of lipid peroxidation representative product [list of references 3] as lipid peroxidation, it is used as the sensitive indicator of weighing the body Radical Metabolism, and its content can reflect objectively that body produces the level of free radical.
2 lipid peroxidations
It is that the main diseases of coronary atherosclerosis is because of [list of references 4] that serum oxidized low-density lipoprotein (OxLDL) raises.Diagnosis and treatment for coronary atherosclerosis, intervention property heart radiology is by means of the development of image apparatus and conduit technology, conduit can be positioned over aortic sinus and near-end coronarius through femoral artery, use balloon tamponade, the atherosis narrow blood vessel of expansion or placement stainless steel stent and strut blood vessel, to improve the blood supply of heart muscle tissue.This technology and surgery's coronary bypass has formed the method that complements one another.The several years patient vessel is narrow once more behind the transluminal coronary angioplasty still has higher probability, warn people when the expansion of seeking narrow blood vessel, should strengthen monitoring, and more need strengthen control [list of references 5] the OxLDL level in the blood circulation to coronary restenosis.
The control of coronary heart disease is atherosclerosis to a great extent, and its key link is to reduce OxLDL, thereby avoids macrophage phagocytic, forms foam cell, and the triggering speckle forms, fibrosis causes tremulous pulse medicated porridge sample to change [list of references 6].So removing OxLDL in blood becomes prevention and treats arteriosclerotic key, also becomes an important ring of coronary heart disease control simultaneously.
OxLDL is intravital free radical source, and macrophage is not attacked natural low density lipoprotein, LDL (LDL), thereby does not cause arteriosclerotic lesion.Therefore antioxidant becomes the target that the research of resisting coronary heart disease pharmaceutics is paid close attention to.Water miscible antioxidant is by preventing lipophilic vitamin E loss, and the LDL in the protection blood avoids oxidation [list of references 2]; The LDL of blood vessel endothelium lower floor then relies on remaining fat antioxidant action.These chemical compounds will be the important sources that exploitation prevents and treats arteriosclerosis and medicaments for coronary disease.
The intravital antioxidant system of 3 machines
Enzyme antioxidant superoxide dismutase (SOD) is to eliminate body O
2 -Main enzyme, be distributed in the endochylema and mitochondrion of cell, there are two kinds of isozyme Cu in it, Zn-SOD (endochylema) and Mn-SOD (mitochondrion), its activity high definition is more removed the ability strong more [list of references 7] of free radical.Catalase (CAT) is to eliminate hydrogen peroxide (H in the body
2O
2) important enzyme, be present in microgranule and the mitochondrion.Reduced glutathion (GSH) can be protected the activity of sulfydryl enzyme as the intravital important protection factor, and it can also make superoxide anion (O under the catalysis of GSH-PX
2 -), hydrogen peroxide (H
2O
2) and fat hydroperoxides (LOOH) become the hypotoxicity material, protection biomembrane and biomacromolecule are avoided radical damage play an important role.The important enzyme that a kind of catalyzing hydrogen peroxide that extensively exists in the glutathion peroxidase (GSH-PX), body decomposes, catalysis GSH plays the effect of protection membrane structure and functional completeness to the reduction reaction of hydrogen peroxide specifically.Glutathione transferase (CST) extensively is present in mammiferous each tissue, content is particularly abundant in the hepatocyte, participate in the important function of detoxification of liver, and can combine with the electrophilic group of chemical substance by catalysis GSH, finally form mercapturic acid and excrete [list of references 8].
The non-enzyme antioxidant is with its cancellation free radical, prevention or interrupt lipid peroxidation, stabilate film and bring into play the antioxidative effect.Mainly comprise: liposoluble substance, as lycopene, vitamin E, beta-carotene, coenzyme Q10 and flavone compound etc.; Water-soluble substances is as vitamin C, CSH etc.In addition, trace element (zinc (Zn), selenium (Se), chromium (Cr), manganese (Mn)) participates in the biosynthesis of enzyme antioxidant, and plays antioxidative effect [list of references 9] with the character of self electron transport.
The present invention is by above-mentioned rationale and cause damage problem to carry out sufficient research and analysis to easy pair cell of myocardial ischemia-reperfusion and tissue, show after deliberation, myocardial ischemia reperfusion injury can further strengthen myocardial infarction area, the cardiac dysfunction degree is heavier than acute myocardial infarction, and case fatality rate is higher.During reperfusion injury, because free radical effect and Ca
2 +Overload has damaged cell membrane and mitochondrion, and permeability of cell membrane is increased, and tissue necrosis causes the various enzymes of myocardial cell to leak outside, and is released into blood, causes that a series of serum zymetologys change [list of references 10].Serum creatine kinase isozyme (CK-MB), the determination of activity of lactate dehydrogenase L DH and glutamic oxaloacetic transaminase, GOT AST can be used as observe myocardial ischemia reperfusion injury degree and medicine resist myocardial ischemia the reperfusion injury curative effect and more after one of index.
During myocardial ischemia reperfusion injury, arterial endothelium is impaired, the prostacyclin (PGI) that mainly results from the coronary blood endothelial cell is synthesized disturbed, subcutaneous collagen tissue in platelet is killed and invested further discharges the vaso-excitor material based on thromboxane A (TXA).TXA can be used as carrier and directly promotes Ca
2 +Interior stream and dense tubular system Ca
2 +Put, thereby promote platelet aggregation and local vasoconstriction, increase the weight of endothelial injury [list of references 10].
Therefore oxygen-derived free radicals is one of key factor that causes reperfusion injury to histiocytic infringement.In myocardial ischemia and the refilling process; the superoxide dismutase (SOD) of cardiac muscle; the content of catalase (CAT) and glutathion peroxidase (GSH-Px) etc. reduces; malonaldehyde (MDA) content increases, so exogenous antioxidant or the free radical scavenger of giving is to ischemia and pour into cardiac muscle again and have significant protective effect [list of references 11].And, improve the endogenous activities of antioxidant enzymes and further alleviate oxygen-derived free radicals induced myocardial injury by suppressing the lipid peroxidation process.
Summary of the invention
In sum; anti-oxidation medicine should become treatment and protect the main medicine that human body cell and tissue is caused damage because of ischemia-reperfusion; it is a carrier with enzyme and non-enzyme antioxidant with the Biodegradable polymer; be coated in the foley's tube on the balloon surface; and the analysis by pharmacological action; it can singly be planted and prepare; again can multiple mixed preparing; can also with anti-angiogenic restenosis medicaments mixed preparing; by local application, can alleviate effectively and reduce because of the final realization treatment of the damage of radical pair human body cell and tissue behind myocardial ischemia-reperfusion cardiac dysfunction.
Provided by the inventionly alleviate postoperative vascular restenosis and radical damage and be coated in the medication coat of balloon surface in the foley's tube, the balloon surface medication coat by the anti-oxidation medicine of 1%-99% or 1%-99% anti-oxidation medicine and anti-angiogenic restenosis medicaments mix and the pharmaceutical carrier of 1%-99% is formed.
Anti-oxidation medicine of the present invention comprises superoxide dismutase (SOD), catalase (CAT), coenzyme Q10, glutathion peroxidase (GSH-PX), lycopene, reduced glutathion (GSH), vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and trace element (zinc (Zn), selenium (Se), chromium (Cr), product behind manganese (Mn) and the process molecular modification thereof, in the said medicine any one or any several drugs all can be prepared with pharmaceutical carrier, wherein, any one content of medicines during several drugs mixes should account for the 1%-99% of the total proportion of medicine;
Described anti-angiogenic restenosis class medicine is anticoagulation class medicine, anticancer class medicine, inhibition vascular smooth muscle cell curing class activity inhibitor, anti-inflammatory drug and immunosuppressant, wherein:
Anticoagulation class medicine comprises aspirin, heparin, hirudin, antiplatelet GPIIb/IIIa receptor antagonist, clopidogrel;
Anticancer class medicine comprises colchicine, paclitaxel;
Suppress vascular smooth muscle cell curing class activity inhibitor and comprise angiogenic peptide, 17-hydroxy-11-dehydrocorticosterone, calcium ion antagonist;
Anti-inflammatory drug comprises dactinomycin, depsidomycin, KanglemycinC, spergualin, cammunomicin, demethomycin, tetranactin, stevastelins, myriocin, gllooxin;
Immunosuppressant comprises rapamycin, the plain A of ring spore enzyme, the plain C of ring spore enzyme, brefeldin A;
Medication coat of the present invention can be made up of the pharmaceutical carrier of any one and 1%-99% in anti-oxidation medicine superoxide dismutase, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and the zinc of 1%-99%, selenium, chromium, the manganese microelement.
Medication coat of the present invention can be made up of mixing several arbitrarily in anti-oxidation medicine superoxide dismutase, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and the zinc of 1%-99%, selenium, chromium, the manganese microelement and the pharmaceutical carrier of 1%-99%; Wherein, the content of any one anti-oxidation medicine in the medicament mixed should account for the 1%-99% of the total proportion of medicine.
Medication coat of the present invention can be by the anti-oxidation medicine superoxide dismutase of 1%-99%, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and zinc, selenium, chromium, in the manganese microelement any one and aspirin, heparin, hirudin, antiplatelet GPIIb/IIIa receptor antagonist, clopidogrel, tazettine, paclitaxel, angiogenic peptide, 17-hydroxy-11-dehydrocorticosterone, calcium ion antagonist, the plain A of ring spore enzyme, dactinomycin, rapamycin, the plain C of ring spore enzyme, brefeldin A, depsidomycin, KanglemycinC, spergualin, cammunomicin, demethomycin, tetranactin, stevastelins, myriocin, the mixing of any one among the gllooxin and the pharmaceutical carrier of 1%-99% are formed; Wherein, the content of any one anti-oxidation medicine in the medicament mixed should account for the 1%-99% of the total proportion of medicine.
Pharmaceutical carrier of the present invention is Biodegradable material and non-degradable material.Biodegradable material comprises copolymer or the blend between PTMC and PLA, Polyethylene Glycol, polyvinylpyrrolidone (PVP), glutin, polyurethane, poly phosphate or the polyglycolic acid ester, its copolymerization or blend ratio are 1%: 99%-99%: in 1% (concentration ratio) scope, and its molecular weight 5000-500000 dalton.
The non-degradable material comprises copolymer or the blend between plastic of poly vinyl acetate and polymethyl methacrylate, sodium alginate, gelatin, arabic gum or the polybutyl methacrylate, its copolymerization or blend ratio are 1%: 99%-99%: in 1% (concentration ratio) scope, and its molecular weight 5000-500000 dalton.
Preparation method provided by the invention comprises two kinds (mainly being the preparations at multicomponent pharmaceutical), and a kind of is with the medicament mixed coating, and another kind is the layering coating.Layering coating should be with anti-angiogenic restenosis class medicine as the intermediate layer, and anti-oxidation medicine is coated in the top layer of air bag.Coating method can adopt the spraying process or the infusion process arbitrary form of medicine coating method, no matter take any method, all should reach coating evenly and its medication coat thickness should be between the 0.1-50 micron, the drug loading of every pair of air bag is between the 10-1000 microgram.
What the preparation method of the embodiment of the invention adopted is spraying process and infusion process, rotatable air bag angle repeats spraying several times in spraying process, it is reached evenly, and the medication coat content on the air bag can be controlled by the concentration of drug solution and the number of times of coating.Its preparation method is as follows:
1. mix coating: pharmaceutical carrier is dissolved in the solvent, adds medicine and stir, after treating fully to dissolve and filtering, evenly be coated in the foley's tube on the balloon surface, and in noble gas solvent flashing, afterwards in vacuum condition dry 12 hours down, ethane via epoxyethane sterilization again.
2. layering coating: pharmaceutical carrier is dissolved in the solvent, adds anti-angiogenic restenosis class medicine and stir, after treating fully dissolving and filtering, evenly be coated in the foley's tube on the balloon surface, and in noble gas solvent flashing; Pharmaceutical carrier is dissolved in the solvent, adds the polyphenoils medicine then and stir, after treating fully to dissolve and filtering, evenly be coated in once more in the foley's tube on the balloon surface, and in noble gas solvent flashing, afterwards in vacuum condition dry 12 hours down, ethane via epoxyethane sterilization again.
The advantage of layering coating is, both can discharge the anti-oxidation medicine skin earlier to reach the purpose of alleviating and reducing because of the damage of radical pair human body cell and tissue behind the myocardial ischemia-reperfusion, the anti-angiogenic restenosis class medicine transition in operation process that can control the intermediate layer is again run off, and just discharges fully and reach lesions position always.
The solvent that compounding pharmaceutical coating solution of the present invention uses is heterocyclic arene class, pure ketone, esters, alkanes, aromatic hydrocarbons and water; Comprise any one of methanol, ethanol, sodium lactate, acetonitrile, isopropyl alcohol, oxolane, acetone, ethyl acetate, dichloromethane, chloroform or purified water.The noble gas that uses in the medication coat preparation process can be any one of other noble gas in nitrogen, helium and the periodic table of chemical element.
The release cycle of anti-oxidation medicine of the present invention is 1 second to 1 hour.
The specific embodiment
Embodiment one: after the 0.3g Polyethylene Glycol is dissolved in 10ml acetone, adding 0.2g superoxide dismutase (SOD) stirs, after dissolving all even filtration, be sprayed on balloon surface in the foley's tube that is covered with the middle medication coat of 0.1g paclitaxel, solvent flashing in nitrogen, and the anglec of rotation repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment two: after the copolymer of 0.2g PTMC and polyurethane (5/95 (mol/mol)) is dissolved in the 10ml acetonitrile, add 0.5g lycopene, 0.01g coenzyme Q10 and 0.01g vitamin E, stir, after dissolving all even filtration, balloon surface in the foley's tube of dip-coating medication coat in the middle of being covered with the 0.1g dactinomycin, solvent flashing in nitrogen, and the anglec of rotation repeats dip-coating several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment three: 0.3g is excellent to be after apparent 370 contrast agent are dissolved in the 10ml ethyl acetate, adding 0.3g coenzyme Q10 and 0.01g rapamycin stirs, after dissolving all even filtration, be expelled to balloon surface in the foley's tube, and the anglec of rotation repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment four: after the copolymer of 0.5g PTMC and polylactic acid (25/75 (mol/mol)) is dissolved in the 10ml acetonitrile, adding 0.1g coenzyme Q10 and 0.2g paclitaxel stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and the anglec of rotation repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment five: after the copolymer of 0.2g PTMC and polyurethane (30/70 (mol/mol)) is dissolved in 10ml ethanol, add the 0.1g coenzyme Q10, stir, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment six: after the 0.4g plastic of poly vinyl acetate is dissolved in 10ml acetone, adding 0.3g coenzyme Q10 and 0.1g ciclosporin A stirs, after dissolving all even filtration, be sprayed on balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment seven: after the copolymer of 0.3g PTMC and polyglycolic acid ester (10/90 (mol/mol)) is dissolved in the 10ml oxolane, add 0.2g superoxide dismutase (SOD) and 0.1g vitamin E, stir, after dissolving all even filtration, be sprayed in the middle of the copolymer (10/90 (mol/mol)) that is covered with 0.1g ciclosporin A and 0.3g PTMC and polylactic acid balloon surface in the foley's tube of medication coat, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment eight: after the copolymer of 0.1g PTMC and polylactic acid (5/95 (mol/mol)) is dissolved in 10ml acetone, adding the 0.2g lycopene stirs, after dissolving all even filtration, be sprayed in the middle of the copolymer (10/90 (mol/mol)) that is covered with 0.1g dactinomycin and 0.3g PTMC and polylactic acid balloon surface in the foley's tube of medication coat, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment nine: after the copolymer of 0.3g PTMC and polylactic acid (10/90 (mol/mol)) is dissolved in the 10ml oxolane, add 0.2g superoxide dismutase (SOD) and 0.1g vitamin E, stir, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment ten: after the copolymer of 0.5g PTMC and polyglycolic acid ester (25/75 (mol/mol)) is dissolved in 10ml ethanol, adding 0.1g beta-carotene and 0.2g paclitaxel stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 11: after the copolymer of 0.3g PTMC and polyurethane (10/90 (mol/mol)) is dissolved in the 10ml isopropyl alcohol, adding the 0.2g vitamin C stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 12: after the copolymer of 0.2g PTMC and poly phosphate (5/95 (mol/mol)) is dissolved in 10ml ethanol, add 0.01g vitamin C, 0.01g coenzyme Q10 and 0.3g vitamin E, stir, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 13: after the copolymer of 0.5g PTMC and polylactic acid (15/85 (mol/mol)) is dissolved in the 10ml acetonitrile, adding 0.02g vitamin C and 0.03g rapamycin stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 14: after the copolymer of 0.3g PTMC and polyglycolic acid ester (25/75 (mol/mol)) is dissolved in the 10ml isopropyl alcohol, adding 0.1g vitamin C and 0.2g paclitaxel stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 15: after the copolymer of 0.4g PTMC and polyurethane (30/70 (mol/mol)) is dissolved in 10ml acetone, adding the plain A of 0.01g vitamin C and 0.01g ring spore enzyme stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 16: after the copolymer of 0.3g PTMC and polyurethane (10/90 (mol/mol)) is dissolved in the 10ml acetonitrile, adding the 0.2g catalase stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 17: after the copolymer of 0.2g PTMC and poly phosphate (5/95 (mol/mol)) is dissolved in 10ml acetone, add 0.1g catalase and 0.1g vitamin E, stir, after dissolving all even filtration, dip-coating balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 18: after the copolymer of 0.5g PTMC and polylactic acid (15/85 (mol/mol)) is dissolved in the 10ml acetonitrile, adding 0.1g catalase and 0.2g rapamycin stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 19: after the copolymer of 0.3g PTMC and polyglycolic acid ester (25/75 (mol/mol)) is dissolved in the 10ml oxolane, adding 0.1g catalase and 0.2g paclitaxel stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 20: after the copolymer of 0.4g PTMC and polyurethane (30/70 (mol/mol)) is dissolved in the 10ml acetonitrile, adding the plain A of 0.01g catalase and 0.1g ring spore enzyme stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Obviously, the above embodiment of the present invention only is for example clearly is described, and is not to be qualification to embodiment of the present invention.Can also make other changes in different forms on the basis of the above description.Here need not also can't give exhaustive to all embodiments.And these belong to conspicuous variation or the change that spirit of the present invention amplified out and still belong among protection scope of the present invention.
List of references:
[1]Basaga，HS.
Biochemical?aspects?of?free?radicals
Biochem?Cell?Biol，68：989-998，1990.
[2]Sohal，R.S.and?Weindruch，R.
Oxidative?stress，caloric?restriction，and?aging.
Science?273：59-63，1996.
[3]Kumar，S.&?Menon，VP.
Changes?in?levels?of?lipid?peroxides?and?activity?of?superoxide?dusmutase?and?catalase?in?diabetesassociated?with?myocardial?infarction
Ind?J?Exp?Biol，30：122-127，1992.
[4]Stryer，L.
Biochem
Spektrum，Akad.Verlag，4.Auflag，1996.
[5]Springer
The?lancet?drug?profiles：Ginkgo?bilobaBeilage?in?der?Internist，34(5)，1-11，1992.
[6]Szibor，M.&?Holtz，J.
Mitochondrial?ageing.
In：Basic?Research?in?Cardiology，Vol.98，No.4，210-218，2003.
[7]Voet，D.&?Voet，JG.
Biochem
VCH，Weinheim，N.Y.，Basel，Cambridge，Tokyo，1.korr.Auflage，504-560，1994.
[8]Takeda，N.
Cardiomyopathies?and?mitochondrial?DNA?mutations
Molecular?and?Cellular?Biochemistry，176：287-290，1997.
[9]Yan，SD.&?Schmidt，AM.&?Anderso，GM.&?Zhang，J.&?Brett，J.et?al.
Enhanced?cellular?oxidant?stress?by?the?interaction?of?advanced?glycation?endothelial?products?withtheir?receptors/binding?proteins
The?Journal?of?Biological?Chemistry，13：9889-9897，1994.
[10]Takeymann，N.&?Matsuo，N.&?Tanaka，T.
Oxidative?damage?to?mitochondria?by?the?Ca++-dependent?inner?membrane?permeability?transitionBiochem.J，294：719-725，1993.
[11]Xiaoyan?Men
Study?no?the?Injury?Caused?by?the?Oxygen-derived?Free?Radicals?at?Heart?Failure?of?CHDHeilongjlang?medical?journa
1004-5775(2005)06-0410-02
Claims (10)
1. can alleviate the postoperative vascular restenosis is coated in balloon surface in the foley's tube with reducing radical damage medication coat for one kind, it is characterized in that, the blood vessel stent drug coating by the anti-oxidation medicine of 1%-99% or 1%-99% anti-oxidation medicine and anti-angiogenic restenosis medicaments mix and the pharmaceutical carrier of 1%-99% is formed.
2. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, it is characterized in that described medication coat can be by the anti-oxidation medicine superoxide dismutase of 1%-99%, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and zinc, selenium, chromium, the pharmaceutical carrier of in the manganese microelement any one and 1%-99% is formed.
3. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, it is characterized in that described medication coat can be by the anti-oxidation medicine superoxide dismutase of 1%-99%, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and zinc, selenium, chromium, arbitrarily several mixing and the pharmaceutical carrier of 1%-99% are formed in the manganese microelement; Wherein, the content of any one anti-oxidation medicine in the medicament mixed should account for the 1%-99% of the total proportion of medicine.
4. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, it is characterized in that described medication coat can be by the anti-oxidation medicine superoxide dismutase of 1%-99%, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and zinc, selenium, chromium, in the manganese microelement any one and aspirin, heparin, hirudin, antiplatelet GPIIb/IIIa receptor antagonist, clopidogrel, tazettine, paclitaxel, angiogenic peptide, 17-hydroxy-11-dehydrocorticosterone, calcium ion antagonist, the plain A of ring spore enzyme, dactinomycin, rapamycin, the plain C of ring spore enzyme, brefeldin A, depsidomycin, KanglemycinC, spergualin, cammunomicin, demethomycin, tetranactin, stevastelins, myriocin, the mixing of any one among the gllooxin and the pharmaceutical carrier of 1%-99% are formed; Wherein, the content of any one anti-oxidation medicine in the medicament mixed should account for the 1%-99% of the total proportion of medicine.
5. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, described medication coat can be by the anti-oxidation medicine superoxide dismutase of 1%-99%, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and zinc, selenium, chromium, any several and aspirin in the manganese microelement, heparin, hirudin, antiplatelet GPIIb/IIIa receptor antagonist, clopidogrel, tazettine, paclitaxel, angiogenic peptide, 17-hydroxy-11-dehydrocorticosterone, calcium ion antagonist, the plain A of ring spore enzyme, dactinomycin, rapamycin, the plain C of ring spore enzyme, brefeldin A, depsidomycin, KanglemycinC, spergualin, cammunomicin, demethomycin, tetranactin, stevastelins, myriocin, the mixing of any one among the gllooxin and the pharmaceutical carrier of 1%-99% are formed; Wherein, the content of any one anti-oxidation medicine in the medicament mixed should account for the 1%-99% of the total proportion of medicine.
6. describedly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube as claim 1,2,3,4,5, it is characterized in that described pharmaceutical carrier can be copolymer or in the blend any one between PTMC and PLA, Polyethylene Glycol, polyvinylpyrrolidone (PVP), glutin, polyurethane, poly phosphate or the polyglycolic acid ester; Perhaps can be copolymer or in the blend any one between plastic of poly vinyl acetate and polymethyl methacrylate, sodium alginate, gelatin, arabic gum or the polybutyl methacrylate, its copolymerization or blend ratio be all 1%: 99%-99%: in 1% scope.
7. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, its preparation method is as follows: pharmaceutical carrier is dissolved in the solvent, adding medicine stirs, after treating fully dissolving and filtration, evenly be coated in the foley's tube on the balloon surface, and in noble gas solvent flashing, afterwards in vacuum condition dry 12 hours down, ethane via epoxyethane sterilization again.
8. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, another kind of preparation method is as follows: pharmaceutical carrier is dissolved in the solvent, adding anti-angiogenic restenosis class medicine stirs, after treating fully dissolving and filtration, evenly be coated in the foley's tube on the balloon surface, and in noble gas solvent flashing; Pharmaceutical carrier is dissolved in the solvent, adds the polyphenoils medicine then and stir, after treating fully to dissolve and filtering, evenly be coated in once more in the foley's tube on the balloon surface, and in noble gas solvent flashing, afterwards in vacuum condition dry 12 hours down, ethane via epoxyethane sterilization again.
9. describedly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the preparation method of the medication coat of balloon surface in the foley's tube as claim 7 or 8, it is characterized in that described solvent adopts any one in methanol, ethanol, sodium lactate, acetonitrile, isopropyl alcohol, oxolane, acetone, ethyl acetate, dichloromethane, chloroform or the purified water; Described noble gas can use any one of other noble gas in nitrogen, helium or the periodic table of chemical element.
10. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, it is characterized in that, described medication coat thickness is between the 0.1-50 micron, and the drug loading of every pair of air bag is between the 10-1000 microgram; The release cycle of described anti-oxidation medicine is 1 second to 1 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101504138A CN101264347A (en) | 2007-11-27 | 2007-11-27 | Drug-eluting coated on surface of sacculus catheter air bag for alleviating vascular restenosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101504138A CN101264347A (en) | 2007-11-27 | 2007-11-27 | Drug-eluting coated on surface of sacculus catheter air bag for alleviating vascular restenosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101264347A true CN101264347A (en) | 2008-09-17 |
Family
ID=39987181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101504138A Pending CN101264347A (en) | 2007-11-27 | 2007-11-27 | Drug-eluting coated on surface of sacculus catheter air bag for alleviating vascular restenosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101264347A (en) |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
| CN102791302A (en) * | 2009-12-11 | 2012-11-21 | 雅培心血管系统有限公司 | Hydrophobic therapueutic agent and solid emulsifier coating for drug coated balloon |
| CN102883753A (en) * | 2010-03-25 | 2013-01-16 | 路通医疗股份有限公司 | Drug releasing coatings for medical devices |
| CN103301513A (en) * | 2013-06-09 | 2013-09-18 | 诸辉 | Preparation method of intravascular stent with pharmaceutical enzyme coating |
| JP2014518724A (en) * | 2011-05-25 | 2014-08-07 | コーディス・コーポレイション | Expandable device coated with rapamycin composition |
| JP2014523267A (en) * | 2011-05-25 | 2014-09-11 | コーディス・コーポレイション | Expandable device coated with paclitaxel composition |
| CN104511084A (en) * | 2014-12-30 | 2015-04-15 | 深圳市信立泰生物医疗工程有限公司 | Balloon catheter |
| CN104857573A (en) * | 2010-03-25 | 2015-08-26 | 路通医疗股份有限公司 | Drug releasing coating for medical device |
| CN105105892A (en) * | 2015-08-04 | 2015-12-02 | 王显 | Medicine elution balloon |
| JP2016510608A (en) * | 2013-03-07 | 2016-04-11 | アボット カーディオバスキュラー システムズ インコーポレイテッド | Implantable medical device comprising a macrocyclic triene lactone drug and a minimum amount of an antioxidant stabilizer and method of manufacture |
| US9694111B2 (en) | 2006-11-20 | 2017-07-04 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9737691B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9751081B2 (en) | 2014-12-01 | 2017-09-05 | Clemson University | Self-regenerating antioxidant catalysts and methods of using the same |
| US9757351B2 (en) | 2006-11-20 | 2017-09-12 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids |
| US9764065B2 (en) | 2006-11-20 | 2017-09-19 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9937159B2 (en) | 2006-11-20 | 2018-04-10 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| CN110935070A (en) * | 2012-10-18 | 2020-03-31 | 米歇尔技术公司 | Drug delivery medical device |
| CN111407930A (en) * | 2020-03-19 | 2020-07-14 | 中国科学院长春应用化学研究所 | Polymer bionic coating and preparation method thereof |
| CN111803718A (en) * | 2020-07-02 | 2020-10-23 | 西安交通大学医学院第二附属医院 | Anti-fibrosis drug sustained-release coating and preparation method thereof |
| CN112642045A (en) * | 2021-01-08 | 2021-04-13 | 北京先瑞达医疗科技有限公司 | Drug coating conveying device and preparation method thereof |
-
2007
- 2007-11-27 CN CNA2007101504138A patent/CN101264347A/en active Pending
Cited By (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9694111B2 (en) | 2006-11-20 | 2017-07-04 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US9757544B2 (en) | 2006-11-20 | 2017-09-12 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US10912931B2 (en) | 2006-11-20 | 2021-02-09 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US10994055B2 (en) | 2006-11-20 | 2021-05-04 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US10485958B2 (en) | 2006-11-20 | 2019-11-26 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US10485959B2 (en) | 2006-11-20 | 2019-11-26 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9937159B2 (en) | 2006-11-20 | 2018-04-10 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US11534430B2 (en) | 2006-11-20 | 2022-12-27 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US9764065B2 (en) | 2006-11-20 | 2017-09-19 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9757351B2 (en) | 2006-11-20 | 2017-09-12 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids |
| US11376404B2 (en) | 2006-11-20 | 2022-07-05 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US10835719B2 (en) | 2006-11-20 | 2020-11-17 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US10881644B2 (en) | 2006-11-20 | 2021-01-05 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US9737691B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| CN102791302A (en) * | 2009-12-11 | 2012-11-21 | 雅培心血管系统有限公司 | Hydrophobic therapueutic agent and solid emulsifier coating for drug coated balloon |
| CN102791302B (en) * | 2009-12-11 | 2017-03-01 | 雅培心血管系统有限公司 | Hydrophobic therapeutic agent for the sacculus of coated with drug and solid emulsifier coating |
| CN104857573A (en) * | 2010-03-25 | 2015-08-26 | 路通医疗股份有限公司 | Drug releasing coating for medical device |
| CN102883753B (en) * | 2010-03-25 | 2015-04-15 | 路通医疗股份有限公司 | Drug releasing coatings for medical devices |
| CN102883753A (en) * | 2010-03-25 | 2013-01-16 | 路通医疗股份有限公司 | Drug releasing coatings for medical devices |
| JP2014523267A (en) * | 2011-05-25 | 2014-09-11 | コーディス・コーポレイション | Expandable device coated with paclitaxel composition |
| JP2014518724A (en) * | 2011-05-25 | 2014-08-07 | コーディス・コーポレイション | Expandable device coated with rapamycin composition |
| CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
| WO2013097717A1 (en) * | 2011-12-27 | 2013-07-04 | 上海微创医疗器械（集团）有限公司 | Drug-eluting balloon tube |
| CN110935070A (en) * | 2012-10-18 | 2020-03-31 | 米歇尔技术公司 | Drug delivery medical device |
| JP2016510608A (en) * | 2013-03-07 | 2016-04-11 | アボット カーディオバスキュラー システムズ インコーポレイテッド | Implantable medical device comprising a macrocyclic triene lactone drug and a minimum amount of an antioxidant stabilizer and method of manufacture |
| CN103301513A (en) * | 2013-06-09 | 2013-09-18 | 诸辉 | Preparation method of intravascular stent with pharmaceutical enzyme coating |
| US9751081B2 (en) | 2014-12-01 | 2017-09-05 | Clemson University | Self-regenerating antioxidant catalysts and methods of using the same |
| CN104511084A (en) * | 2014-12-30 | 2015-04-15 | 深圳市信立泰生物医疗工程有限公司 | Balloon catheter |
| CN105105892B (en) * | 2015-08-04 | 2017-03-29 | 北京康容源医疗器械有限公司 | A kind of medicament elution sacculus |
| CN105105892A (en) * | 2015-08-04 | 2015-12-02 | 王显 | Medicine elution balloon |
| CN111407930B (en) * | 2020-03-19 | 2021-01-08 | 中国科学院长春应用化学研究所 | Polymer bionic coating and preparation method thereof |
| CN111407930A (en) * | 2020-03-19 | 2020-07-14 | 中国科学院长春应用化学研究所 | Polymer bionic coating and preparation method thereof |
| CN111803718A (en) * | 2020-07-02 | 2020-10-23 | 西安交通大学医学院第二附属医院 | Anti-fibrosis drug sustained-release coating and preparation method thereof |
| CN111803718B (en) * | 2020-07-02 | 2022-02-25 | 西安交通大学医学院第二附属医院 | Anti-fibrosis drug sustained-release coating and preparation method thereof |
| CN112642045A (en) * | 2021-01-08 | 2021-04-13 | 北京先瑞达医疗科技有限公司 | Drug coating conveying device and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101264347A (en) | Drug-eluting coated on surface of sacculus catheter air bag for alleviating vascular restenosis | |
| US10471184B2 (en) | Coating formulations for scoring or cutting balloon catheters | |
| EP1789107B1 (en) | Medical stent provided with inhibitors of atp synthesis | |
| Mukerabigwi et al. | Therapeutic nanoreactors as in vivo nanoplatforms for cancer therapy | |
| CN103736154B (en) | Medicinal coating balloon catheter | |
| CN110201243B (en) | Composite drug coating balloon catheter and preparation method thereof | |
| CN103561791B (en) | Be coated with the distensible devices of paclitaxel composition | |
| EP1834637A1 (en) | Preventive/therapeutic composition for free radical disease | |
| EP1390014B1 (en) | Composition for use in a method for treating hyperplasia | |
| JP5801874B2 (en) | Improved formulations for drug-coated medical devices | |
| EP1338278A1 (en) | Administration of resveratrol to prevent or treat restenosis following coronary intervention | |
| JPH07503010A (en) | Pharmaceutically active antioxidant-containing composition and method for preventing and treating restenosis after angioplasty using the composition | |
| US8647680B2 (en) | Methods and compositions for treatment of lesioned sites of body vessels | |
| BR112012024244B1 (en) | BALLOON CATHETER FOR DRUG ADMINISTRATION IN A TISSUE | |
| CN1321090A (en) | Treatment of vascular restenosis | |
| CN101264345A (en) | Degradable blood vessel stent drug-eluting capable of reducing incidence rate of advanced thrombus | |
| CN101264346A (en) | Degradable polymer blood vessel stent drug-eluting containing anticoagulant choline phosphate composition | |
| CN112704686B (en) | Preparation method of calcium phosphate-rapamycin composite medicine, preparation method of medicine coating balloon and medicine coating balloon | |
| CN106267377A (en) | Drug coated balloon catheter | |
| CN106806948B (en) | Application of PI3K/mTOR dual inhibitor | |
| CN100431627C (en) | Blood ressel stent medicinal conting layer capable of relieving free radical harmful to cell after blood deficiency refilling | |
| CN204219578U (en) | Containing the coating in blood vessel sacculus of Thalidomide layer | |
| PL218200B1 (en) | Controlled releases system containing temozolomide | |
| EP3746006A1 (en) | Methods and devices for reducing vacular smooth muscle cell proliferation | |
| CN101513540A (en) | Drug-eluting coronary artery stent and method for preparing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080917 |